Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VGX-1027 (GIT 27) is an isoxazole compound with various immunomodulatory properties.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 42.00 | |
10 mg | In stock | $ 68.00 | |
25 mg | In stock | $ 142.00 | |
50 mg | In stock | $ 229.00 | |
100 mg | In stock | $ 367.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 46.00 |
Description | VGX-1027 (GIT 27) is an isoxazole compound with various immunomodulatory properties. |
In vitro | VGX-1027 enhances survival rates and ameliorates clinical and histopathological signs in the NZB/NZW F1 model of systemic lupus erythematosus, thereby improving disease progression. It prevents the spontaneous development of Type 1 diabetes in NOD mice and counters the acceleration of diabetes induced either by cyclophosphamide assault or by the adoptive transfer of diabetogenic spleen cells in NOD mice. Furthermore, VGX-1027 reduces clinical symptoms of diabetes induced by MLD-STZ and inhibits pathological histological changes in the pancreas. |
In vivo | VGX-1027 exhibits inhibitory effects on the proliferation of gut bacterial antigen-reactive CD4+ CD25- T cells in vitro. It significantly suppresses the accumulation of TNF-α and nitrites induced by IL-1β/IFN-γ, and notably enhances cell survival by interfering with the toxic effects of cytokines. |
Synonyms | VGX1027, VGX 1027, GIT 27 |
Molecular Weight | 205.21 |
Formula | C11H11NO3 |
CAS No. | 6501-72-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 20.5 mg/mL (100 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VGX-1027 6501-72-0 Apoptosis Immunology/Inflammation IL Receptor TNF Interleukin Tumor Necrosis Factor Receptor VGX1027 inhibit Interleukin Related GIT27 Inhibitor TNF Receptor VGX 1027 TNFR GIT 27 GIT-27 inhibitor